LPTX Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -- compared to Leap Therapeutics's net margin of --. Leap Therapeutics's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Leap Therapeutics has a consensus price target of $9.83, signalling upside risk potential of 182.57%. On the other hand Armata Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 238.16%. Given that Armata Pharmaceuticals has higher upside potential than Leap Therapeutics, analysts believe Armata Pharmaceuticals is more attractive than Leap Therapeutics.

Leap Therapeutics has a beta of 0.168, which suggesting that the stock is 83.238% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.895%.

Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Leap Therapeutics quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Leap Therapeutics's net income of -$18.2M is lower than Armata Pharmaceuticals's net income of -$5.5M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 77.96x versus 749.94x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

CervoMed has a net margin of -- compared to Leap Therapeutics's net margin of --. Leap Therapeutics's return on equity of -- beat CervoMed's return on equity of --.

Leap Therapeutics has a consensus price target of $9.83, signalling upside risk potential of 182.57%. On the other hand CervoMed has an analysts' consensus of $20.00 which suggests that it could grow by 765.8%. Given that CervoMed has higher upside potential than Leap Therapeutics, analysts believe CervoMed is more attractive than Leap Therapeutics.

Leap Therapeutics has a beta of 0.168, which suggesting that the stock is 83.238% less volatile than S&P 500. In comparison CervoMed has a beta of 1.782, suggesting its more volatile than the S&P 500 by 78.196%.

Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CervoMed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. CervoMed pays out -- of its earnings as a dividend.

Leap Therapeutics quarterly revenues are --, which are smaller than CervoMed quarterly revenues of --. Leap Therapeutics's net income of -$18.2M is lower than CervoMed's net income of -$4.8M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while CervoMed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 77.96x versus 23.47x for CervoMed. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -- compared to Leap Therapeutics's net margin of -31993.31%. Leap Therapeutics's return on equity of -- beat Inovio Pharmaceuticals's return on equity of -98.72%.

Leap Therapeutics has a consensus price target of $9.83, signalling upside risk potential of 182.57%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $10.67 which suggests that it could grow by 367.84%. Given that Inovio Pharmaceuticals has higher upside potential than Leap Therapeutics, analysts believe Inovio Pharmaceuticals is more attractive than Leap Therapeutics.

Leap Therapeutics has a beta of 0.168, which suggesting that the stock is 83.238% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 0.842, suggesting its less volatile than the S&P 500 by 15.846%.

Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Leap Therapeutics quarterly revenues are --, which are smaller than Inovio Pharmaceuticals quarterly revenues of $100.8K. Leap Therapeutics's net income of -$18.2M is higher than Inovio Pharmaceuticals's net income of -$25.2M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 77.96x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Leap Therapeutics's net margin of 18.02%. Leap Therapeutics's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

Leap Therapeutics has a consensus price target of $9.83, signalling upside risk potential of 182.57%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 527.8%. Given that Protalix BioTherapeutics has higher upside potential than Leap Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Leap Therapeutics.

Leap Therapeutics has a beta of 0.168, which suggesting that the stock is 83.238% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.711, suggesting its less volatile than the S&P 500 by 28.881%.

Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Leap Therapeutics quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Leap Therapeutics's net income of -$18.2M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 77.96x versus 3.84x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.